The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Opens in a new tab or window Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences announced on Friday. The decision was made ...

There are two antibody-drug conjugates approved for the treatment of bladder cancer: sacituzumab govitecan (Trodelvy), which targets the Trop-2 protein on cancer cells, and enfortumab vedotin ...

the most common form of bladder cancer. The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or ...

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who ...

1. Gilead Sciences said it is voluntarily withdrawing its bladder cancer drug, sacituzumab govitecan (Trodelvy), after a confirmatory trial in patients with metastatic urothelial cancer failed to ...

The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% [101] Association of CK19 with UPII detected pN0 patients with ...

Gilead Sciences plans to voluntarily withdraw U.S. accelerated approval for Trodelvy in metastatic urothelial cancer ... approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients ...